Axtria® Inc. Announces a Strategic Agreement to Improve Productivity & Effectiveness Through Incentives and Bonuses for All Global Commercial Teams on the Cloud-Based Axtria SalesIQ™ Platform

BERKELEY HEIGHTS, N.J. - Wednesday, November 30th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Axtria, a global big data analytics company, is pleased to announce a strategic agreement with Boehringer Ingelheim (a top 20 pharmaceutical manufacturer) to provide end-to-end Incentive Compensation services to its global commercial teams. As part of the agreement, over 12,000 users across Boehringer Ingelheim’s global markets will be deployed on Axtria’s SalesIQ. There are already 3,500 users in the US and Japan live on the platform today.

Previously, all bonus and incentive processes at Boehringer Ingelheim were localized within each business unit and region. With a focus on driving field force effectiveness, Boehringer Ingelheim aims to standardize on a modern, enterprise-grade platform that align compensation strategies and implements best practices globally.

“Axtria proved that they not only have a strong platform and experience to deploy in an agile way a state of the art bonuses and incentives platform but also proved they have a strong global experience on how to bring to the next level Customer Facing Roles motivation through bonuses and incentives therefore impacting their productivity and effectiveness.” said Dave Arnold, Head of Customer Engagement Excellence at Boehringer Ingelheim.

Axtria SalesIQ is an integrated, cloud based sales planning and operations platform covering Territory Alignment, Call Planning, Incentive Compensation and Field Reporting. It is built on the Salesforce.com platform and integrates natively with Veeva CRM.

As part of the transformation, Boehringer Ingelheim expects Axtria SalesIQ to deliver:

    A scalable, enterprise-grade incentive compensation platform
    A global solution that drives standardization across markets
    Flexibility to work with localized data, currencies, credits and languages
    Agility to adapt and grow with evolving business needs
    A reduction in administration errors, often caused by spreadsheets and manual processes
    Improvements in controls and transparency across business processes

“We are excited to be partnering with Boehringer Ingelheim on this strategic initiative” said Jassi Chadha, Founder and CEO of Axtria. “This is a testament to the impact that our cloud solutions have on Commercial Operations processes. We look forward to delivering on the vision, improving field force effectiveness and incentivizing the right behaviors across the globe.”

To learn more about Axtria and their cloud solutions, please visit www.axtria.com

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

About Axtria

Axtria is a global big data analytics company. We help leaders across the Life Sciences and Financial Services industries make better data-driven decisions.

We help to optimize business strategy by delivering cutting edge analytics from the broadest set of data sources, combined with deep technical and domain expertise. We enable commercial excellence by eliminating spreadsheets and delivering analytical guidance to the field through Axtria SalesIQ, our cloud based sales planning and operations platform. We are leaders in managing data using the latest cloud information management and big data technologies.

We have more than 800 employees worldwide, we are growing rapidly, and we are proud to count 8 of the top 10 global Life Sciences companies and 2 of the Top 5 global banks as our customers.

Trademarks

Axtria and Axtria SalesIQ are registered trademarks of Axtria. Other names may be trademarks of their respective owners.

Contacts

Axtria

Andrew Keleher, +1-877-929-8742

Senior Director of Marketing

andrew.keleher@axtria.com









Permalink: http://me-newswire.net/news/19140/en

Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany

KONSTANZ, Germany & OSAKA, Japan - Wednesday, November 30th 2016 [ME NewsWire]

    Decision follows the successful initiation of TIDES, the global Phase 3 clinical trial to evaluate the efficacy of a two-dose schedule of Takeda’s dengue vaccine candidate
    40% of the world’s population lives under the threat of the dengue virus
    Manufacturing plant is major step towards meeting important unmet needs in dengue prevention

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease. Forty percent of the world’s population lives under the threat of the dengue virus, which causes an estimated 390 million infections and more than 20,000 deaths each year around the world in people of all ages.

“This manufacturing plant investment reinforces Takeda’s strong support for our global vaccine strategy in general, and dengue in particular. The new plant will provide millions of people with access to a medicine that addresses a huge unmet medical need. It underlines our commitment to improve the lives of people worldwide,” says Dr. Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda.

“Our colleagues in Singen have vast experience in lyophilisation technology, which is key for the manufacturing process of Takeda’s dengue vaccine finished product,” notes Thomas Wozniewski. Initial construction activities will start immediately, and the facility should be ready for production in 2019.

On September 7, 2016 Takeda vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES). TIDES is now enrolling approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study is a Phase 3 double-blind, randomized, placebo-controlled trial of Takeda’s live-attenuated tetravalent dengue vaccine candidate. The study is evaluating the efficacy of the vaccine candidate to protect subjects against symptomatic dengue fever caused by any of the four dengue virus serotypes, regardless of age and whether the individual has previously been exposed to the virus. The study is also evaluating vaccine safety and immunogenicity, with two doses of the vaccine candidate or placebo administered 90 days apart.

Dr. Rajeev Venkayya, President of Takeda Vaccines, adds “This dengue vaccine production facility is another strong indication of Takeda’s long-term commitment to vaccines. The progress of the dengue TIDES clinical trial, our partnership with the Bill & Melinda Gates Foundation to eradicate polio, the recent initiation of the world’s first field efficacy trial for a norovirus vaccine, and our work with the U.S. Government to develop a Zika vaccine, together demonstrate how Takeda is dedicated to developing and providing vaccines to protect people in need wherever they are.”

About the Dengue Vaccine Candidate (TAK-003)
Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ‘backbone’ for all four vaccine viruses. Takeda’s dengue vaccine is being developed to support the protection of populations and individuals at risk for dengue across geographies whether or not they have had previous exposure to dengue virus, including: children and adults, travelers and those living in endemic areas.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Additional information about Takeda is available through its corporate website, www.takeda.com.

Contacts

Media Contacts:

Takeda Pharmaceutical Company Limited

Tsuyoshi Tada, +81 (0) 3-3278-2417

tsuyoshi.tada@takeda.com









Permalink: http://me-newswire.net/news/19136/en

Patient Safety Movement Foundation Names Dr. Jannicke Mellin-Olsen to Its Board of Directors

Dr. Mellin-Olsen, the Driving Force for the Landmark Helsinki Declaration on Patient Safety in Anaesthesiology, Joins the Patient Safety Movement as First International Board Member

IRVINE, Calif. - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- The Patient Safety Movement Foundation (PSMF) has named long-time patient safety advocate Jannicke Mellin-Olsen, MD, DPH, to its Board of Directors. In addition to her full-time clinical post in Bærum Hospital in Oslo, Norway, Dr. Mellin-Olsen serves as Secretary of the European Society of Anesthesiology and President-Elect of the World Federation of Societies of Anaesthesiologists.

“We feel very fortunate to have Dr. Mellin-Olsen join our board,” said Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation. “For over 25 years, Dr. Mellin-Olsen has been extremely active internationally in promoting safe anesthesiology practices, dedicating her life to saving patients from avoidable harm and death. With the help of respected and committed leaders like Dr. Mellin-Olsen, we hope to one day eliminate all preventable patient deaths on every continent.”

Dr. Mellin-Olsen began working on patient safety initiatives during her residence training at Trondheim University Hospital, Norway, where she earned her specialty in 1992. She is currently full-time practicing clinical anaesthesiologist in Bærum Hospital, Norway. She has served in the UN Peace Keeping Forces in Lebanon and for the Red Cross in Pakistan and Serbia, and for 10 years, she was the medical director for Europe, Middle East, and Africa for MedAire, Inc., which provides remote medical services to patients in the air and at sea. While serving on the European Board of Anaesthesiology, she chaired the Patient Safety and Quality Committee, and later, during her presidency, she was the driving force for the landmark Helsinki Declaration on Patient Safety in Anaesthesiology, which launched in 2010. Dr. Mellin-Olsen also serves as the Foundation’s Regional Network Chair, spreading the mission of the Foundation to stakeholders across Europe. She is the Secretary of the European Society of Anaesthesiology and the President-Elect of the World Federation of Societies of Anaesthesiologists.

“I’m honored to serve on the Board of Directors of the Patient Safety Movement Foundation, a natural extension of my patient safety advocacy work around the world,” said Dr. Mellin-Olsen. “When a patient entrusts the health system with his or her life, it is our sworn duty as clinicians to protect that patient from any preventable harm. I look forward to helping expedite their efforts internationally and involve more stakeholders across the globe in their mission to eliminate preventable deaths in hospitals.”

The Patient Safety Movement Foundation board members include; Dr. Steven Barker, Professor Emeritus of Anesthesiology, University of Arizona, and CSO of Masimo; Robin Betts, MBA-HM, RN, Assistant Vice President of Quality of Patient Safety; Alicia Cole, Executive Director of the Alliance for Safety Awareness for Patients; Omar Ishrak, Chairman and CEO of Medtronic plc; David Mayer, MD, Vice President of Quality and Safety for MedStar Health; Jim Messina, CEO of The Messina Group; Charlie Miceli, Vice President of Information Systems & Supply Chain for Fletcher Allen Health Care; Tamra E. Minnier, RN, MSN, FACHE, Chief Quality Officer, University of Pittsburgh Medical Center; Steven Moreau, President & Chief Executive Officer of St. Joseph Hospital; and Michael A. E. Ramsay, MD, FRCA, Chairman of the Department of Anesthesiology, Baylor University Medical Center, and President of the Baylor Research Institute.

About the Patient Safety Movement Foundation

More than 200,000 people die every year in U.S. hospitals in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare, to reduce that number of preventable deaths to 0 by 2020 (0x2020). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems and solutions of patient safety. The Foundation also convenes Patient Safety, Science and Technology summits. The first annual Summit was held in January 2013 and brought together some of our nation’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact recipes to meet patient safety challenges, encouraging medical technology companies to share the data for whom their products are purchased, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.

@0x2020 #patientsafety #0x2020

Contacts

Patient Safety Movement Foundation

Irene Paigah, 858-859-7001

irene@paigah.com









Permalink: http://me-newswire.net/news/19132/en

Nordson EFD Explains How to Choose Dispensing Tips in New Series of Educational Videos

Videos help viewers learn quickly and easily how to select the right dispensing tip for a particular fluid and application

EAST PROVIDENCE, R.I. - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Nordson EFD, a Nordson company (NASDAQ: NDSN) and the world’s leading manufacturer of precision fluid dispensing systems, introduces a new Better Dispensing™ How-To Video series. These first three short but highly instructional videos, hosted by EFD Application Specialist Tom Muccino, provide best practices when selecting a dispense tip.

“The dispensing tip is one of the most important parts of the dispensing system,” said Muccino in the first overview how-to video. “So you don’t want to choose just any tip that works. You want to choose the best tip for the application.”

Nordson EFD manufactures hundreds of different dispensing tips with varying lengths, gauges, angles, and other features designed to optimize dispensing repeatability and accuracy for each fluid type and application.

    The first video provides a brief overview of the different types of dispense tips available and types of fluids they’re best used with.
    The second video outlines the most optimal dispense tips to use with medium-to-thick viscosity fluids to achieve benefits such as increased productivity.
    The third video provides useful information about dispense tips that prevent wicking and dripping when dispensing low-viscosity fluids. It also outlines specialty tips that prevent premature curing of cyanoacrylates in the cannula.

These three Better Dispensing How-To Videos are the first in a series of educational videos from Nordson EFD that will provide best practices to help manufacturers improve dispensing processes to achieve greater throughput while reducing rejects, rework, and fluid waste. Visit nordsonefd.com/HowTo to watch future installments.

For more information, email Nordson EFD at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.

About Nordson EFD

Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.

About Nordson Corporation

Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51461484&lang=en

Contacts

Nordson EFD

Natalie Tomasso +1-401-431-7173 (USA)

Marketing Communications Specialist

natalie.tomasso@nordsonefd.com

or

Ideagraphics, Inc.

Gaylen Whittier (agency), +1-401-438-9727

gaylen@ideagrfx.com

or

Nordson EFD

Global

Natalie Tomasso, +1-401-431-7173

natalie.tomasso@nordsonefd.com



Europe

+44 (0) 1582 666334

europe@nordsonefd.com



China

+86 (21) 3866 9006

china@nordsonefd.com

or

Japan

+81 (03) 5762 2760

japan@nordsonefd.com



SEAsia

+65 6796 9522

sin-mal@nordsonefd.com

or

India

+91 80 4021 3600

india@nordsonefd.com



Permalink: http://me-newswire.net/news/19130/en

AURAK Launches Innovation Week Program

Ras Al Khaimah, United Arab Emirates - Thursday, November 24th 2016 [ME NewsWire]

The American University of Ras Al Khaimah (AURAK) has launched its comprehensive program for the second annual Innovation Week initiative, as decreed by His Highness Sheikh Mohammed bin Rashid Al Maktoum, UAE Vice President and Prime Minister and Ruler of Dubai.

The university held an innovation competition for students earlier this month, giving them the opportunity to put forward their projects, the best of which have been selected for display at this week’s innovation exhibition at Ras Al Khaimah Exhibition Center.

The winning project was a mobile phone application, available on iPhone and Android, which utilizes QR code technology which allows users to exchange jigsaw pieces in order to complete a picture. With the UAE National Day approaching, the first jigsaw that creators, Aisha El Allam and Maryam Abdulla, coded into the application was a picture of the seven sheikhs of the seven emirates.

Speaking of their inspiration for creating the app, which was under the supervision of Dr. Said Elnaffar, Aisha commented, “We all love and appreciate the peace and prosperity that the UAE offers us, so we created this app with the intention of allowing people to connect and socialize based on their mutual love for this country. The app was also designed so that people have to physically meet and talk to each other, rather than ‘socializing’ in cyberspace.”

The second place project, overseen by mentor Dr. Abdul Gafoor Puthiyaveetil, was produced by two junior biotechnology students: Najath Abdulkareem and Nada Anwar. With the rapidly increasing population of the planet, they reasoned, food production is more important than ever. Their adapted idea, vertical farming, deals with growing food indoors on a tiered platform using a combination of sunlight and LED lights. The layout maximizes efficiency through reusing water and saving space. The pair of students have successfully grown the likes of basil, parsley, rosemary and mint within their own homes.

A number of other projects were also on display, including a conceptual design for a smartphone screen which can produce text in braille to assist the visually impaired, as well as an innovative teaching method based on sensory stimulation which has had positive results in the field of special needs education. The projects were viewed by the crown prince of Ras Al Khaimah, H. H. Sheikh Mohammad bin Saud Al Qassimi, who congratulated the students on their inventiveness.

Commenting at the event, AURAK president, Professor Hassan Hamdan Al Alkim, commented, “This is a great opportunity to demonstrate to the community the extent of the innovation and research going on at the university. We are producing knowledge in all fields and we have students, who are aided by top-class professors, who are being given the opportunity to actively participate in this process.”

Contacts

Eóin Brown

Marketing and Public Relations Department, +971 7 2210900 Ext: 1325

eoin.brown@aurak.ac.ae









Permalink: http://www.me-newswire.net/news/19119/en

AHF’s Campaign to Fight HIV Amongst Young Women and Girls (GIRLS ACT) Heads to South Africa, Nigeria & Kenya

KAMPALA, Uganda - Friday, November 25th 2016 [ME NewsWire]

(BUSINESS WIRE)-- The AIDS Healthcare Foundation, Africa Bureau will launch its campaign to fight HIV amongst young women and girls aged 15-24 in South Africa and Nigeria on the 25th and in Kenya on the 29th of November. This is coming after a successful launch of the same campaign in Uganda about 3 weeks ago.

The campaign dubbed Girls’ ACT (Awareness Campaign Tour) is largely informed by the compelling fact that young women and adolescent girls account for one in five new HIV infections in Africa and are almost three times more likely than their male counterparts to be living with HIV in sub-Saharan Africa. This is highlighted in the 2013 report of the Joint United Nations Program on HIV/AIDS (UNAIDS), which states that almost 60% of all new HIV infections among young people aged 15–24 occurred among adolescent girls and young women and 80% of them live in sub-Saharan Africa. “These statistics spotlights the disproportion that young women and girls face in the HIV/AIDS epidemic and begs for more strategic and relatable approaches," said Dr. Adetayo Towolawi, Country Program Manager, AHF Nigeria. “It is therefore imperative that we reach out to these young women and girls in an aggressive manner, leaving no stone unturned and no one behind.”

Girls’ ACT, is a multi-institutional drive that primarily aims to; a) scale up HIV/AIDS prevention services in order to curb new HIV infections amongst this population sub-group, and b) ensure that young people living with HIV are enrolled and retained in HIV care for improved health outcomes. “To achieve this, AHF is working together with partners from government, civil society and business, to offer a range of health services including HIV and TB tests, Sexual reproductive health, menstrual health and self-esteem, counseling on gender-based violence, and pro-bono legal services for victims of violation or abuse,” added Hilary Thulare, Country Program Director, AHF South Africa “Together we can empower our communities to ACT against HIV and sexual violence and promote positive living with dignity amongst young women and adolescent girls.”

“Our safe space programs and interactions with young people in Kenya, has given us a great opportunity to understand the needs of young women and girls better, and insights on how best to support them,” said Dr. Wamae Maranga, Country Director, AHF Kenya. “Majority of the girls do not visit health facilities for various reasons, and those living with HIV continue to struggle with self-esteem issues and stigma, which negatively impact their health. Therefore, if we want to get different results, we must do things differently and that is where an out-of-the-box initiative such as the GIRLS ACT comes to bare.”

The GIRLS ACT campaign, which takes the form of a concert-like caravan, aims to bring services closer to communities, targeting young women and adolescent girls from all walks of life, different socioeconomic groupings and dwellings. However, their male counterparts and the general community as key gatekeepers for young girls’ protection will also benefit by accessing HIV/AIDS related information & services as well as other connect services.

“Young women and girls are a major focus for us at AHF right now. We want to see them live healthy lives and make informed decisions about their health, so we can break the cycle of new infections,” said Terri Ford, Chief of Global advocacy and Policy. “We cannot afford to be complacent about this and to see how the GIRLS ACT has gained so much buy-in and huge followership, is proof that we need young people at the heart of these interventions. We have to keep them alive and well”!

Speaking on the success of the campaign in Uganda, AHF Africa Bureau Chief, Dr. Penninah Iutung shared thus “At the Uganda launch, Girls ACT was well received by stakeholders and partners alike; who have committed to working with us on this project as we move to more districts.” Beyond the strengthened partnerships, the most significant and remarkable outcome from the launch was witnessing young women and girls who had fallen out of treatment, get re-enrolled. That was an absolute indication that we are on the right track”. “We will continue to work closely with young people across our country programs to see what works best for them, in order to ensure they have access to the much needed care and information,” she enthused.

Contacts

AHF AFRICA MEDIA CONTACT:

Kemi Gbadamosi

Senior Manager, PR & Communications, Africa Bureau

oluwakemi.gbadamosi@aidshealth.org

or

Alice Kayongo

Regional Policy & Advocacy Manager, E/W Africa

Alice.kayongo@aidshealth.org

or

Larissa Klazinga

Regional Policy & Advocacy Manager, Southern Africa

Larissa.klazinga@aidshealth.org









Permalink: http://me-newswire.net/news/19124/en

TRIGO Group and PSA Group Partnership

PARIS - Tuesday, November 29th 2016 [ME NewsWire]

(BUSINESS WIRE)-- TRIGO has been awarded a strategic contract by PSA Group to provide extensive quality services in France for the upcoming years.

The cooperation between TRIGO and PSA Group started two decades ago and has been developed in many locations worldwide where PSA Group operates. As a result of a proposal opportunity launched in France in 2016, TRIGO became the trusted quality service provider at 13 French PSA manufacturing sites.

TRIGO’s innovative quality solutions are significantly facilitating the automotive manufacturer’s operations and improving its competitiveness by covering the complete OEM manufacturing process and offering a comprehensive quality service portfolio, including Containment and Sorting actions, Quality Firewall, Vehicle Launch Support, In-process and Final Vehicle Inspection, Software Update, Initial Sample Management, Non-conformity Analysis, Supplier Training and Audit, and more.

Additionally, TRIGO’s leading position in providing technical OEM services such as Mechanical Rework, Electronic Diagnosis, Electrical Rework, Saddlery, Painting, Bare Sheet and Painted Car Body Repair benefited its position to be chosen as a strategic quality partner by the French manufacturer.

Furthermore, the TRIGO Academy offering extensive Quality Trainings and premium Technical Expertise in Inspection and Technical Repair to OEM and Tier-1 customers as well as TRIGO internal associates, has also contributed to set up a successful cooperation with PSA Group for the upcoming years.

"We are very proud to strengthen further our partnership with PSA Group and to become the trusted quality services provider in France. This is a clear market recognition of TRIGO’s successful strategic development and unique market positioning in France and worldwide. Our competitive, extensive and technical quality service portfolio is a key asset for the automotive OEMs to successfully achieve the challenging quality targets required in this industry. This is also a strong reward to our operational teams who deliver a best-in-class daily service to PSA Group while sharing the values of operational excellence and customer satisfaction,” says Julien Laforets, Managing Director of TRIGO France.

ABOUT TRIGO GROUP

Founded in 1997, TRIGO is a multinational company providing operational Quality Management solutions for the manufacturing sector, especially in the transportation industries. With a team of more than 7000 professionals present in 20+ countries across 4 continents, TRIGO offers a comprehensive portfolio of Quality Inspection, Engineering, and Management Services all along the supply chain.

For more information, please visit www.trigo-group.com

ABOUT PSA GROUP

With sales and revenue of €54 billion in 2015, the PSA Group designs unique automotive experiences and delivers mobility solutions that provide freedom and enjoyment to customers around the world. The Group leverages the models from its three brands, Peugeot, Citroën and DS, as well as a wide array of mobility services, such as Free2Move, to meet the evolving needs and expectations of automobile users. PSA is the European leader in terms of CO2 emissions, with average emissions of 104.4 grams of CO2 per kilometer in 2015, and an early innovator in the field of autonomous and connected cars, with 1.8 million such vehicles worldwide. It is also involved in financing activities through Banque PSA Finance and in automotive equipment via Faurecia.

For more information, please visit www.groupe-psa.com/en

Contacts

TRIGO Group

Mercédesz Trum

Group Marketing Manager, +36 30 485 83 53

mercedesz.trum@trigo-group.com









Permalink: http://www.me-newswire.net/news/19134/en